Targeted Delivery of Nanoparticle-Encapsulated Chemotherapeutics in the Management of Triple-Negative Breast Cancer: An Empirical Case Study

Abstract

Triple-negative breast cancer (TNBC) remains a significant clinical challenge due to its aggressive nature and lack of targeted therapies. This study investigates the efficacy of a novel nanoparticle formulation designed for the targeted delivery of chemotherapeutics directly to TNBC cells. Utilizing in vitro and in vivo models, we demonstrate enhanced cytotoxic effects and reduced systemic toxicity compared to conventional treatments. Our findings indicate that this novel delivery mechanism significantly improves therapeutic outcomes, providing a foundation for future clinical applications. These results highlight the potential of nanotechnology in revolutionizing TNBC treatment protocols, paving the way for personalized medicine strategies in oncology.